Back

EcDNA-borne PVT1 fusion stabilizes oncogenic mRNAs

Yi, H.; Zhang, S.; Swinderman, J.; Wang, Y.; Kanakaveti, V.; Hung, K. L.; Wong, I. T.-L.; Srinivasan, S.; Curtis, E. J.; Bhargava-Shah, A.; Li, R.; Jones, M. G.; Luebeck, J.; Zhao, Y.; Belk, J. A.; Kraft, K.; Shi, Q.; Yan, X.; Pritchard, S. K.; Liang, F. M.; Felsher, D. W.; Gilbert, L. A.; Bafna, V.; Mischel, P. S.; Chang, H.

2025-04-03 cancer biology
10.1101/2025.04.01.646515 bioRxiv
Show abstract

Extrachromosomal DNA (ecDNA) amplifications are prevalent drivers of human cancers. We show that ecDNAs exhibit elevated structural variants leading to gene fusions that produce oncogene fusion transcripts. The long noncoding RNA (lncRNA) gene PVT1 is the most recurrent structural variant across cancer genomes, with PVT1-MYC fusions arising most frequently on ecDNA. PVT1 exon 1 is the predominant 5 partner fused to MYC or other oncogenes on the 3 end. Mechanistic studies demonstrate that PVT1 exon 1 confers enhanced RNA stability for fusion transcripts, which requires PVT1 exon 1 interaction with SRSF1 protein. Genetic rescue of MYC-addicted cancer models and isoform-specific single-cell RNA sequencing of tumors reveal that PVT1-MYC better supports MYC dependency and better activates MYC target genes in vivo. Thus, the mutagenic landscape of ecDNA contributes to genome instability and generates chimeric fusions of lncRNA and mRNA genes, selecting PVT1 5 region as a stabilizer of oncogene mRNAs.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.